-
1Academic Journal
Συγγραφείς: Юлия Владимировна Останкова, Александр Владимирович Семенов, Елена Борисовна Зуева, Арег Артемович Тотолян
Πηγή: HIV Infection and Immunosuppressive Disorders; Том 11, № 1 (2019) ; ВИЧ-инфекция и иммуносупрессии; Том 11, № 1 (2019) ; 2077-9828 ; 10.22328/2077-9828-2019-11-1
Θεματικοί όροι: Хронический вирусный гепатит В, оккультный гепатит В, коморбидность, генотип ВГВ, молекулярная эпидемиология
Relation: https://hiv.bmoc-spb.ru/jour/article/downloadSuppFile/363/146; https://hiv.bmoc-spb.ru/jour/article/downloadSuppFile/363/147; https://hiv.bmoc-spb.ru/jour/article/downloadSuppFile/363/148; https://hiv.bmoc-spb.ru/jour/article/downloadSuppFile/363/149; https://hiv.bmoc-spb.ru/jour/article/downloadSuppFile/363/150; https://hiv.bmoc-spb.ru/jour/article/downloadSuppFile/363/151; Yim H.J., Lok A.S. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology, 2006, v.43(2 S.1), P. S173–S181. DOI:10.1002/hep.20956; Raimondo G., Allain J. P., Brunetto M. R., Buendia M. A., Chen D. S., Colombo M., Craxi A., Donato F., Ferrari C., Gaeta G. B., Gerlich W. H., Levrero M., Locarnini S., Michalak T., Mondelli M. U., Pawlotsky J. M., Pollicino T., Prati D., Puoti M., Samuel D., Shouval D., Smedile A., Squadrito G., Trepo C., Villa E., Will H., Zanetti A. R., Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol, 2008, 49, P. 652–657. DOI:10.1016/j.jhep.2008.07.014; Guo J.T., Guo H. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. Antiviral research, 2015, vol. 122, P. 91–100. DOI:10.1016/j.antiviral.2015.08.005; Dandri M., Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut, 2012, V. 61, № 1, P.i6–i17. DOI:10.1136/gutjnl-2012-302056; Семенов А. В., Останкова Ю. В., Файзуллаев Х. Н., Казакова Е. И., Козлов А. В., Мусабаев Э. И., Тотолян Арег А. Кольцевая ковалентно замкнутая ДНК ВГВ как маркер распространенности оккультного гепатита В у пациентов c ВГВ, ВГД и ВГС инфекцией в Узбекистане // ЖМЭИ. 2016. № 5. с. 43-49.; Samal J., Kandpal M., Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin. Microbiol. Rev., 2012, 25, P. 142–163. DOI:10.1128/CMR.00018-11; Joint United Nations Programme on HIV/AIDS., United Nations. Global Report: UNAIDS Report on the Global AIDS epidemic: 2012. Geneva: UNAIDS; 2012. 103. A5 p. p. http://www.unaids.org/en/resources/documents/2012/20121120_UNAIDS_Global_Report_2012; WHO Prevention and control of viral hepatitis infection: frame work for global action 2012. Geneva: WHO, 2012. http://www.who.int/hiv/pub/hepatitis/Framework/en/; Дадашева А,Э., Мамедов М.К., Михайлов М.И. О двух типах гpупп с высоким pиском инфициpования виpусами гепатитов В и С: эпидемиологическое и клиническое значение // В миpе виpусных гепатитов. 2011. № 1. С. 12–14.; Nelson P., Mathers B., Cowie B., Hagan H., Jarlais D., Horyniak D., Degenhardt L. The epidemiology of viral hepatitis among people who inject drugs: Results of global systematic reviews. The Lancet, 2011, V. 378, №9791, P. 571–583. DOI:10.1016/S0140-6736(11)61097-0; Rossi С., Shrier I., Marshall L., Cnossen S., Schwartzman K., Klein M.B., Schwarzer G., Greenaway C. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: A systematic review and meta-analysis. PLoS ONE, 2012, V. 7, №9, P. e44611. DOI:10.1371/journal.pone.0044611; Argani H., Akhtarishojaie E. Levamizole enhances immune responsiveness to intra-dermal and intra-muscular hepatitis B vaccination in chronic hemodialysis patients. J. Immune Based Ther. Vaccines, 2006, 4, P.3. DOI:10.1186/1476-8518-4-3; Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol., 2006, 44(1 Suppl), P.S6-S9. DOI:10.1016/j.jhep.2005.11.004; Burnett R.J., François G., Kew M.C., Leroux-Roels G., Meheus A., Hoosen A.A., Mphahlele M.J. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int., 2005, 25(2), P.201–213. DOI:10.1111/j.1478-3231.2005.01054.x; Kapembwa K.C., Goldman J.D., Lakhi S., Banda Y., Bowa K., Vermund S.H., Mulenga J., Chama D., Chi B.H. HIV, Hepatitis B, and Hepatitis C in Zambia. J. Glob. Infect. Dis., 2011, v.3(3), P.269–274. DOI:10.4103/0974-777X.83534; Vallet-Pichard A., Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J. Hepatol., 2006, 44(1), P.S28–S34. DOI:10.1016/j.jhep.2005.11.008; Osborn M.K., Guest J.L., Rimland D. Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease. HIV Med., 2007, 8(5), P.271-279. DOI:10.1111/j.1468-1293.2007.00469.x; Демиденко Т.П., Неверов В.А. Вирусные гепатиты / Под ред. Ю.В. Лобзина. СПб, 2011. 229с.; Thio C.L., Seaberg E.C, Skolasky R., Phair J., Visscher B., Muñoz A., Thomas D.L. HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS). Lancet, 2002, v.360, p. 1921–1926. DOI:https://doi.org/10.1016/S0140-6736(02)11913-1; Agyeman A.A., Ofori-Asenso R. Prevalence of HIV and hepatitis B coinfection in Ghana: a systematic review and meta-analysis. AIDS. Res. Ther., 2016, vol.13:23. DOI:10.1186/s12981-016-0107-x; Ramezani A., Banifazl M., Mohraz M., Rasoolinejad M., Aghakhani A. Occult hepatitis B virus infection: A major concern in HIV-infected patients: Occult HBV in HIV. Hepat. Mon., 2011, v.11(1), P.7-10.; WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection Geneve, Switzerland: WHO, 2015. http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/; Mphahlele M.J., Lukhwareni A., Burnett R.J., Moropeng L.M., Ngobeni J.M. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J. Clin. Virol., 2006, v.35(1), P.14–20. DOI:10.1016/j.jcv.2005.04.003; Filippini P., Coppola N., Pisapia R., Scolastico C., Marrocco C., Zaccariello A., Nacca C., Sagnelli C., De Stefano G., Ferraro T., De Stefano C., Sagnelli E. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS, 2006, v.20(9), P.1253–1260. DOI:10.1097/01.aids.0000232232.41877.2a; Brichler S., Lagathu G., Chekaraou M.A., . Le Gal F, Edouard A., Dény P., Césaire R., Gordien E. African, Amerindian and European hepatitis B virus strains circulate on the Caribbean Island of Martinique. J. Gen. Virol., 2013, vol. 94 (Pt 10), P. 2318-2329. DOI:10.1099/vir.0.055459-0; Kumar S., Stecher G., Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Molecular Biology and Evolution. 2016, vol. 33, №7. P. 1870-1874. DOI:10.1093/molbev/msw054; Coffin C.S., Mulrooney-Cousins P.M., Osiowy C., van der Meer F., Nishikawa S., Michalak T.I., van Marle G., Gill M.J. Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy. J. Clin. Virol., 2014, vol.60(4), P.347-353. DOI:10.1016/j.jcv.2014.04.021; Gupta S., Singh S. Occult Hepatitis B Virus infection in ART-Naïve HIV-Infected patients seen at a tertiary care center in North India. BMC Infection Diseases, 2010, 10, p.53. DOI:10.1186/1471-2334-10-53; Honarmand A., Pourahmad M., Solhjoo K., Kohan M., Davami M.H., Mostafavi Zadeh S.K. Occult hepatitis B demonstrated by anti-HBc and HBV DNA in HIV-positive patients. Rep. Biochem. Mol. Biol., 2014, v.3(1), P.38-42.; Alvarez-Munoz M.T., Maldonado-Rodriguez A., Rojas-Montes O., Torres-Ibarra R., Gutierrez-Escolano F., Vazquez-Rosales G., Gomez A., Munoz O., Torres J., Lira R. Occult hepatitis B virus infection among Mexican human immunodeficiency virus-1-infected patients. World J. Gastroenterol., 2014, vol.20(37), P.13530-13537. DOI:10.3748/wjg.v20.i37.13530; Bautista-Amorocho H., Castellanos-Domínguez Y.Z., Rodríguez-Villamizar L.A., Velandia-Cruz S.A., Becerra-Peña J.A., Farfán-García A.E. Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: high prevalence of occult hepatitis B and F3 subgenotype dominance. PLoS One, 2014, vol.9(12):e114272. DOI:10.1371/journal.pone.0114272; Cohen Stuart J.W., Velema M., Schuurman R., Boucher C.A., Hoepelman A.I. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J. Med. Virol., 2009, vol.81(3), P.441–445. DOI:10.1002/jmv.21422; Marite B., Montalvo M.C., Rodriguez Lde L., Sariego S., Verdasquera D., Vincent M., Gutiérrez A., Sánchez M. Occult hepatitis B in Cuban HIV patients. MEDICC Rev., 2011, v.13(2), P.32–37.; Fabris P., Biasin M.R., Giordani M.T., Berardo L., Menini V., Carlotto A., Miotti M.G., Manfrin V., Baldo V., Nebbia G., Infantolino D. Impact of occult HBV infection in HIV/HCV co-infected patients: HBV-DNA detection in liver specimens and in serum samples. Curr. HIV Res., 2008, v.6(2), P.173–179. DOI : 10.2174/157016208783885029; Esmail M.A., Mahdi W.K., Khairy R.M., Abdalla N.H. Genotyping of occult hepatitis B virus infection in Egyptian hemodialysis patients without hepatitis C virus infection. J. Infect. Public Health, 2016, v.9(4), P.452-457. DOI:10.1016/j.jiph.2015.11.018; Kim K.H., Chang H.Y., Park J.Y. Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers. Clin. Mol. Hepatol., 2014, vol. 20 (3), P. 251-260. DOI:10.3350/cmh.2014.20.3.251; Останкова Ю.В., Семенов А.В., Буркитбаев Ж.К., Савчук Т.Н., Тотолян Арег А. Генетические варианты вируса гепатита B у первичных доноров в г. Астана, Казахстан // Инфекция и иммунитет. 2016. Т. 6. № 4. с. 359–366.; Wiersma S. T., McMahon B., Pawlotsky J.-M., Thio C. L., Thursz Ma., Gee Lim S., Ocama P., Esmat G., Maimuna M., Bell D., Vitoria M., Eramova I., Lavanchy D., Dusheiko G. WHO. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver International, 2011, vol.31, Issue 6, p. 755-761. DOI:10.1111/j.1478-3231.2010.02373.x; Sagnelli E., Pisaturo M., Martini S., Filippini P., Sagnelli C., Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J. Hepatol., 2014, v.6(6), P.384–393. DOI:10.4254/wjh.v6.i6.384
Διαθεσιμότητα: https://hiv.bmoc-spb.ru/jour/article/view/363
-
2
Συγγραφείς: Юлия Владимировна Останкова, Александр Владимирович Семенов, Елена Борисовна Зуева, Арег Артемович Тотолян
Πηγή: HIV Infection and Immunosuppressive Disorders ; ВИЧ-инфекция и иммуносупрессии
Θεματικοί όροι: Хронический вирусный гепатит В, оккультный гепатит В, коморбидность, генотип ВГВ, молекулярная эпидемиология
Διαθεσιμότητα: https://openrepository.ru/article?id=387508